Supply Chain Map
CVSCIK 64803

CVS HEALTH Corp

EDGAR filings
Customers
2
2 federal agencies
Suppliers
11
9 disclosed
Top supplier share
37%
of HRMY revenue · 3M to 2026-03-31
Top supplier by $
$96.8B
MCK · FY to 2026-03-31
Federal obligations
$5.9M
FY2026 · USAspending.gov
Latest period
Jun 30, 2026
10-K filed 2026-08-11
SuppliersCustomersMCK24% · $96.8BMCK · 24% of their revenue · $96.8B · FY to 2026-03-31 · 10-K filed 2026-05-08CAH28% · $71.2BCAH · 28% of their revenue · $71.2B · FY to 2026-06-30 · 10-K filed 2026-08-11CELGENE CORP /DE/11.5% · $1.8BCELGENE CORP /DE/ · 11.5% of their revenue · $1.8B · FY to 2018-12-31 · 10-K filed 2019-02-26HRMY38% · $330.0MHRMY · 38% of their revenue · $330.0M · FY to 2025-12-31 · 10-K filed 2026-02-24Endo International plc16% · $321.8MEndo International plc · 16% of their revenue · $321.8M · FY to 2023-12-31 · 10-K filed 2024-03-06ARDX13.4% · $16.2MARDX · 13.4% of their revenue · $16.2M · 3M to 2026-06-30 · 10-Q filed 2026-08-06AMRXnamedAMRX · named of their revenue · FY to 2025-12-31 · 10-K filed 2026-02-27AVADEL PHARMACEUTICALS PLCnamedAVADEL PHARMACEUTICALS PLC · named of their revenue · FY to 2024-12-31 · 10-K filed 2025-03-03GIFTnamedGIFT · named of their revenue · FY to 2025-12-31 · 10-K filed 2026-03-18Health and Human Servicesfederal · $5.9MDepartment of Health and Human Services (federal): $5.9M in FY2026 across 5 awardsExecutive Office of the Presfederal · $3.0MExecutive Office of the President (federal): $3.0M in FY2023 across 3 awardsCVS
Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 11

Companies that disclose CVS as a major customer, as a share of their own revenue. 9 active, 2 lapsed.

Company% of their revenueEst. $ from CVSPeriodTrendStatusSource
HRMY
Harmony Biosciences Holdings, Inc.
 37%$79.7M 3M 2026-03-31
3M ending 2021-03-31: 35%3M ending 2022-03-31: 38%3M ending 2023-03-31: 35%3M ending 2024-03-31: 42%3M ending 2025-03-31: 40%3M ending 2026-03-31: 37%−3.0pp
Active 10-Q 2026-05-07
CVS Caremark accounted for 37% of gross product revenue;
10-Q filed 2026-05-07 Period 3M 2026-01-01 to 2026-03-31 (37%)Accession 0001104659-26-056720
Caremark LLC accounted for 38% of gross product revenue;
10-K filed 2026-02-24 Period FY 2025-01-01 to 2025-12-31 (38%)Accession 0001104659-26-018859
CVS Caremark accounted for 40% of gross product revenue;
10-Q filed 2026-05-07 Period 3M 2025-01-01 to 2025-03-31 (40%)Accession 0001104659-26-056720
CVS Caremark, which accounted for 39% of gross accounts receivable, PANTHERx, which accounted for 31% of gross accounts receivable and Accredo, which accounted for 30% of gross accounts receivable.For the year ended December 31, 2025, three customers accounted for 100% of gross product revenue;
10-K filed 2026-02-24 Period FY 2024-01-01 to 2024-12-31 (39%)Accession 0001104659-26-018859
CVS Caremark accounted for 42% of gross product revenue;
10-Q filed 2024-04-30 Period 3M 2024-01-01 to 2024-03-31 (42%)Accession 0001558370-24-006203
CVS Caremark accounted for 37% of gross product revenue;
10-K filed 2026-02-24 Period FY 2023-01-01 to 2023-12-31 (37%)Accession 0001104659-26-018859
CVS Caremark accounted for 35% of gross product revenue;
10-Q filed 2024-04-30 Period 3M 2023-01-01 to 2023-03-31 (35%)Accession 0001558370-24-006203
As of December 31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (“CVS Caremark”), which accounted for 39% of gross accounts receivable;
10-K filed 2025-02-25 Period FY 2022-01-01 to 2022-12-31 (42%)Accession 0001558370-25-001441
CVS Caremark accounted for 38% of gross product revenues;
10-Q filed 2023-05-02 Period 3M 2022-01-01 to 2022-03-31 (38%)Accession 0001558370-23-007571
CVS Caremark accounted for 36% of gross product revenue;
10-K filed 2024-02-22 Period FY 2021-01-01 to 2021-12-31 (36%)Accession 0001558370-24-001466
Pantherx accounted for 38% of gross product revenues CVS Caremark accounted for 35% of gross product revenues; and Accredo accounted for 27% of gross product revenues.The Company depends on a single source supplier for its product and active pharmaceutical ingredient.
10-Q filed 2022-05-03 Period 3M 2021-01-01 to 2021-03-31 (35%)Accession 0001558370-22-006729
CAH Distributor
CARDINAL HEALTH INC
 28%$71.2B FY 2026-06-30
FY ending 2022-06-30: 25%FY ending 2023-06-30: 25%FY ending 2024-06-30: 24%FY ending 2025-06-30: 30%FY ending 2026-06-30: 28%−2.0pp
Active 10-K 2026-08-11
CVS Health 28 % 30 % 24 % 22 % 26 %
10-K filed 2026-08-11 Period FY 2025-07-01 to 2026-06-30 (28%), FY 2024-07-01 to 2025-06-30 (30%), FY 2023-07-01 to 2024-06-30 (24%)Accession 0000721371-26-000038
CVS Health 30 % 24 % 25 % 26 % 22 %
10-K filed 2025-08-12 Period FY 2022-07-01 to 2023-06-30 (25%)Accession 0000721371-25-000079
CVS Health 24 % 25 % 25 % 22 % 23 %
10-K filed 2024-08-14 Period FY 2021-07-01 to 2022-06-30 (25%)Accession 0000721371-24-000056
MCK Distributor
MCKESSON CORP
 24%$96.8B FY 2026-03-31
FY ending 2026-03-31: 24%
Active 10-K 2026-05-08
Sales to our largest customer, CVS Health Corporation (“CVS”), accounted for approximately 24% of our total consolidated revenues in fiscal 2026.
10-K filed 2026-05-08 Period FY 2025-04-01 to 2026-03-31 (24%)Accession 0000927653-26-000069
Endo International plc
Endo International plc
 16%$321.8M FY 2023-12-31
FY ending 2022-12-31: 4%FY ending 2023-12-31: 16%+12.0pp
Active 10-K 2024-03-06
CVS Health Corporation (1) 16 % 4 % — %
10-K filed 2024-03-06 Period FY 2023-01-01 to 2023-12-31 (16%), FY 2022-01-01 to 2022-12-31 (4%)Accession 0001593034-24-000007
ARDX
ARDELYX, INC.
 13.4%$16.2M 3M 2026-06-30
3M ending 2026-03-31: 12.1%3M ending 2026-06-30: 13.4%+1.3pp
Active 10-Q 2026-08-06
Caremark, LLC 13.4 % — % 12.8 % — %
10-Q filed 2026-08-06 Period 3M 2026-04-01 to 2026-06-30 (13.4%)Accession 0001437402-26-000044
Caremark, LLC 12.1 % — %
10-Q filed 2026-04-30 Period 3M 2026-01-01 to 2026-03-31 (12.1%)Accession 0001437402-26-000022
CELGENE CORP /DE/
CELGENE CORP /DE/
 11.5%$1.8B FY 2018-12-31
FY ending 2013-12-31: 9.3%FY ending 2014-12-31: 9.8%FY ending 2015-12-31: 10.7%FY ending 2016-12-31: 12%FY ending 2017-12-31: 12.5%FY ending 2018-12-31: 11.5%−1.0pp
Active 10-K 2019-02-26
CVS Health Corp. 11.5 % 12.5 % 12.0 % 9.2 % 9.7 %
10-K filed 2019-02-26 Period FY 2018-01-01 to 2018-12-31 (11.5%), FY 2017-01-01 to 2017-12-31 (12.5%), FY 2016-01-01 to 2016-12-31 (12%)Accession 0000816284-19-000014
CVS Health Corp. 12.5 % 12.0 % 10.7 % 9.7 % 7.9 %
10-K filed 2018-02-07 Period FY 2015-01-01 to 2015-12-31 (10.7%)Accession 0000816284-18-000005
CVS 10.7 % 9.8 % 9.3 % 8.2 % 7.6 %
10-K filed 2016-02-11 Period FY 2014-01-01 to 2014-12-31 (9.8%), FY 2013-01-01 to 2013-12-31 (9.3%)Accession 0001628280-16-011012
AMAG PHARMACEUTICALS, INC.
AMAG PHARMACEUTICALS, INC.
 10%$47.2M FY 2018-12-31
FY ending 2016-12-31: 10%FY ending 2017-12-31: 10%FY ending 2018-12-31: 10%±0.0pp
Lapsed
Last seen 2018-12-31
 10-K 2019-03-01
Caremark, LLC < 10% < 10% 10 %
10-K filed 2019-03-01 Period FY 2018-01-01 to 2018-12-31 (10%), FY 2017-01-01 to 2017-12-31 (10%), FY 2016-01-01 to 2016-12-31 (10%)Accession 0000792977-19-000036
VIVUS INC
VIVUS INC
 9%$7.3M FY 2013-12-31
FY ending 2012-12-31: 50%FY ending 2013-12-31: 9%−41.0pp
Lapsed
Last seen 2013-12-31
 10-K 2014-02-28
CVS 9 % 50 %
10-K filed 2014-02-28 Period FY 2013-01-01 to 2013-12-31 (9%), FY 2012-01-01 to 2012-12-31 (50%)Accession 0001047469-14-001523
AMRX
Amneal Pharmaceuticals, Inc.
 Named— FY 2025-12-31 —Active 10-K 2026-02-27
Our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc. and CVS Health Corporation, accounted for approximately 71%, 70% and 70% of total net sales of products for the years ended December 31, 2025, 2024 and 2023, respectively.
10-K filed 2026-02-27 Period FY 2025-01-01 to 2025-12-31Accession 0001723128-26-000011
AVADEL PHARMACEUTICALS PLC
AVADEL PHARMACEUTICALS PLC
 Named— FY 2024-12-31 —Active 10-K 2025-03-03
As of December 31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (“Caremark”), which accounted for 53% of gross accounts receivable;
10-K filed 2025-03-03 Period FY 2024-01-01 to 2024-12-31, FY 2023-01-01 to 2023-12-31Accession 0001012477-25-000010
GIFT
GIFTIFY, INC.
 Named— FY 2025-12-31 —Active 10-K 2026-03-18
Major retailers such as Amazon, Best Buy, CVS, and Dell have leveraged these solutions to enhance their customer offerings and drive additional revenue from gift cards without compromising product value.
10-K filed 2026-03-18 Period FY 2025-01-01 to 2025-12-31Accession 0001493152-26-010887

Federal contracts 2

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $9.0M in the latest fiscal year shown per agency.

AgencyObligatedFiscal year AwardsTrendLargest award
Department of Health and Human Services
Food and Drug Administration
 $5.9MFY 2026 5$126.9M → $6.9M → $5.9M 75F40126F19003
BEST 3 TASK ORDER; HEALTH CARE DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS. EO 14398
Award 75F40126F19003 on USAspending.gov ↗ Largest of 5 awards in FY2026: $7.0M obligated
Executive Office of the President
Executive Office of the President
 $3.0MFY 2023 3 11316023F0020WHO
COVID TESTING SERVICES
Award 11316023F0020WHO on USAspending.gov ↗ Largest of 3 awards in FY2023: $1.8M obligated

Named as competitors

Companies this filer names as competitors.

AMZNWMTWalgreens Boots Alliance, Inc.

Alerts are coming

Get an email when CVS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.

We store only your email, the page you signed up from and the time. Privacy